CD4+CD25+ regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis

Clinical Immunology

Volumn 125, Issue 1, 2007, Pages 34-42

  Jee, Y ^a,b   Piao, W H ^a   Liu, R ^a   Bai, X F ^c   Rhodes, S ^a   Rodebaugh, R ^a   Campagnolo, D I ^a   Shi, F D ^a   Vollmer, T L ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Jeju National University   (South Korea)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

CD4+CD25+ regulatory T cells; EAE; GA

Indexed keywords

CYTOKINE; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMMUNOLOGICAL TOLERANCE; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH2 CELL; TREATMENT RESPONSE;

ADOPTIVE TRANSFER; ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOSUPPRESSIVE AGENTS; MICE; PEPTIDES; T-LYMPHOCYTES, REGULATORY;

EID: 34548510355     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.05.020     Document Type: Article

References (35)

1. Teitelbaum D., Aharoni R., Arnon R., and Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 9724-9728
2. Teitelbaum D., Fridkis-Hareli M., Arnon R., and Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64 (1996) 209-217
3. Lisak R.P., Zweiman B., Blanchard N., and Rorke L.B. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J. Neurol. Sci. 62 (1983) 281-293
4. Aharoni R., Teitelbaum D., Sela M., and Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10821-10826
5. 2 type induced by copolymer 1. J. Neuroimmunol. 91 (1998) 135-146
6. 2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler. 7 (2001) 209-219
7. Duda P.W., Krieger J.I., Schmied M.C., Balentine C., and Hafler D.A. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J. Immunol. 165 (2000) 7300-7307
8. en-Nun B.A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M., and Kerlero de Rosbo N. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 243 (1996) S14-S22
9. Burns J., and Littlefield K. Failure of copolymer I to inhibit the human T-cell response to myelin basic protein. Neurology 41 (1991) 1317-1319
10. Aharoni R., Teitelbaum D., Arnon R., and Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 634-639
11. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., Brenner T., Arnon R., and Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4872-4876
12. Jee Y., Liu R., Bai X.F., Campagnolo D.I., Shi F.D., and Vollmer T.L. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?. Int. Immunol. 18 (2006) 537-544
13. + T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J. Clin. Immunol. 24 (2004) 155-161
14. high T regulatory cells and their IL-10 production in multiple sclerosis. J. Neuroimmunol. 144 (2003) 125-131
15. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004) 971-979
16. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182 (2001) 18-32
17. + suppressor T cells: more questions than answers. Nat. Rev., Immunol. 2 (2002) 389-400
18. + T cells and the control of autoimmune disease. Curr. Opin. Immunol. 16 (2004) 695-701
19. + regulatory cells within the central nervous system. J. Immunol. 175 (2005) 3025-3032
20. + T cell activation and experimental autoimmune encephalomyelitis. J. Immunol. 172 (2004) 4686-4690
21. + regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6 (2005) 1152-1159
22. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6449-6454
23. + T cells in patients with MS: effects of glatiramer acetate. 57th Annual Neurology Meeting. American Academy, Miami Beach Convention Center (2005) A269
24. Sean Riminton D., Korner H., Strickland D.H., Lemckert F.A., Pollard J.D., and Sedgwick J.D. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice. J. Exp. Med. 187 (1998) 1517-1528
25. Bai X.F., Li O., Zhou Q., Zhang H., Joshi P.S., Zheng X., Liu Y., Wang Y., and Zheng P. CD24 controlled expression and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J. Exp. Med. 200 (2004) 447-458
26. + regulatory T cells. Nat. Immunol. 4 (2003) 330-336
27. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
28. + regulatory T cells. Int. Immunol. 16 (2004) 249-256
29. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169 (2002) 4712-4716
30. + regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 15434-15439
31. Read S., Malmstrom V., and Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192 (2000) 295-302
32. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., and Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3 (2002) 135-142
33. Fernandez-Martin A., Gonzalez-Rey E., Chorny A., Ganea D., and Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 36 (2006) 318-326
34. + T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175 (2005) 7898-7904
35. - cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J. Immunol. 172 (2004) 5213-5221